The World Health Organization (WHO) validated on Friday the
BBIBP-CorV COVID-19 vaccine developed by China’s Sinopharm for emergency use.
“This afternoon, WHO gave emergency use listing to
Sinopharm Beijing’s COVID-19 vaccine, making it the sixth vaccine to receive
WHO validation for safety, efficacy and quality,” said WHO
Director-General Dr. Tedros Adhanom Ghebreyesus at a press briefing.
“This expands the list of vaccines that COVAX can buy,
and gives countries confidence to expedite their own regulatory approval, and
to import and administer a vaccine,” he said.
In an official press release, WHO Assistant-Director General
for Access to Health Products Dr. Mariangela Simao said that the addition of
China’s Sinopharm COVID-19 vaccine has been approved for emergency use by the World Health Organisation (WHO).
This development was contained in a statement on Friday in which WHO said the decision was part of efforts to improve access to vaccines to curb the spread of the coronavirus.
Sinopharm is the sixth vaccine after Pfizer/BioNTech, Astrazeneca-SK Bio, Serum Institute of India, Janssen and Moderna vaccines, listed for emergency use.
The emergency use listing (EUL), according to the global health body, will also provide more options for countries interested in accessing vaccines via the United Nations-led COVAX facility African countries are procuring vaccines via the COVAX facility.
Saturday, 8 May 2021, 3:18 pm
A COVID-19 vaccine produced in China has been given the
green light for global rollout, potentially paving the way
for its use in underserved countries, the World Health
Organization (WHO) announced on Friday.
The UN agency
has approved the Sinopharm vaccine for emergency use, which
is a prerequisite for inclusion in the global vaccine
solidarity initiative, COVAX.
The
vaccine is easy to store, making it suitable for locations
with limited resources, and proved 79 per cent effective in
clinical trials.
“The addition of this
vaccine has the potential to rapidly accelerate COVID-19 vaccine
access for countries seeking to protect health workers and
May 09, 2021
It has been recommended for adults 18 years and older in a two-dose schedule
The World Health Organisation (WHO) has granted approval to the Covid-19 vaccine made by the Chinese state-owned company Sinopharm.
WHO has listed the Sinopharm Covid-19 vaccine for emergency use, giving the green light for its global roll-out.
The Sinopharm vaccine is produced by Beijing Bio-Institute of Biological Products Co Ltd, a subsidiary of China National Biotec Group (CNBG).
“The addition of this vaccine has the potential to rapidly accelerate COVID-19 vaccine access for countries seeking to protect health workers and populations at risk,” said Dr Mariângela Simão, WHO Assistant-Director General for Access to Health Products. “We urge the manufacturer to participate in the COVAX Facility and contribute to the goal of more equitable vaccine distribution.”